2014

Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

NEW YORK, Sept. 27, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

http://www.reportlinker.com/p01006955/Therapy-Trends--Multiple-Sclerosis----KOL-Insight--and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Charting the Future Multiple Sclerosis Market Landscape

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance

A detailed forecast data analysis spreadsheet model comparing critical market parameters including

Timely event-driven market forecast report and data analysis updates over the next 12 months

Mapping Future Events to Product Sales Forecasts

The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:

Historical MS sales from 2006–2011

Forecast MS sales from 2012-2016

Key competitors and drug developers

Predicted product positioning

Current and late-stage pipeline drugs

Future event mapping to forecast data points

Comparative clinical trial results

Interactive Product and Market Forecast Data Model

FirstWord's MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.

Market size

Product sales

Company forecasts

Company, brand, and drug class

Mechanism of action

Future events

Forecasts and Analysis Updated Within Days of Major Market Events

Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.

Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

Understand the Unique Benefits of Consensus Outlook

Evaluate future sales forecasts and predicted market growth

Map your market parameters and chart commercial prospects

Assess market share by company and product

Tailor your strategic and investment focus based on the competition

Set proactive launch and branding strategies

Keep up with event-driven market data updates

Forecast Data Model (Excel)

Tabs:

Market size

Product sales

Company forecast

Mechanism of action

Events

Forecast Analysis Report (PDF)

Contents:

Analysis Highlights

Multiple Sclerosis Marketplace

Key Multiple Sclerosis Developers

Multiple Sclerosis Class Dynamics

Gilenya (fingolimod; Novartis Mitsubishi Tanabe) Forecast

Tysabri (natalizumab; Biogen/Elan) Forecast

Copaxone (glatiramer acetate; Teva) Forecast

Avonex (interferon beta-1a; Biogen) Forecast

Betaseron (interferon beta-1b; Bayer) Forecast

Rebif (interferon beta-1a; Merck) Forecast

Extavia (interferon beta-1b; Novartis) Forecast

BG-12 (dimethyl fumarate; Biogen) Forecast

Aubagio (teriflunomide; Sanofi) Forecast

Laquinimod (Teva/Active Biotech) Forecast

Lemtrada (alemtuzumab; Genzyme/Sanofi) Forecast

Daclizumab HYP (Biogen/Abbott) Forecast

Ocrelizumab (Biogen/Roche/Biogen) Forecast

To order this report:

Pathology Industry: Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.